Current and future status of JAK inhibitors

  title={Current and future status of JAK inhibitors},
  author={Donal Mclornan and Joanna Pope and Jason Gotlib and Claire N. Harrison},
  journal={The Lancet},

JAK inhibitors: special issue foreword

This special issue collates the latest evidence for JAK inhibitor use in rheumatoid arthritis and evaluates aspects such as cardiovascular safety, infection risks, venous thromboembolism risks, and the potential for malignancy.

JAK inhibitors and COVID-19

Whether a class effect of JAKi may be emerging in COVID-19 treatment, although at the moment the convincing data are for baricitinib only is discussed, because the precise timing of treatment will be very important in future trials.

Targeted Immunotherapy for Autoimmune Disease

Emerging therapies aim to induce immune tolerance without compromising immune function, using advanced molecular engineering techniques, to treat autoimmune diseases.

Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review

Supporting the implication of the IFN-γ-chemokine signaling axis in the pathogenesis of vitiligo is supported, however, more studies are required to determine the ideal dosage of JAK inhibitors, and to identify other inflammatory pathways that may be implicated in the Pathogenesis of this condition.

Trends of Treatment Development in Rheumatoid Arthritis: Promise, Progress, and Challenges

The most exciting recently established or ongoing novel drugs and approaches according to the clinical trial database maintained by the United States National Library of Medicine are reviewed and discussed, providing a reference significant for the accurate treatment of RA and the research direction in the future.

Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis – an option beyond ruxolitinib

Fedratinib presents a much needed option of treatment, particularly, for patients failing Ruxolitinib, with response rates that are quite similar, Nonetheless, there remain important questions including sequencing and options for combining therapy.

Update on VEXAS and role of allogeneic bone marrow transplant: Considerations on behalf of the Chronic Malignancies Working Party of the EBMT

An overview of the current VEXAS data/ therapeutic evidence is provided and the curative potential of allo-HCT is discussed whilst highlighting the efforts required for generation of robust data able to inform therapeutic decisions.

Research progress in the treatment of rheumatoid arthritis

This article focuses on the review of new developments in rheumatoid arthritis treatment drugs and methods, which have shown obvious advantages in recent years.



Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases

The status of the pan-JAK and selective JAK inhibitors approved or in clinical trials are summarized, the rationale for selective targeting of JAKs in inflammatory and autoimmune diseases is discussed, and almost a dozen of which currently are being evaluated inclinical trials are discussed.

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

The biology of JAKs is discussed from a translational perspective, focusing on recent insights from clinical trials, the development of novel agents and the use of jakinibs in a spectrum of immune and inflammatory diseases.

Network pharmacology of JAK inhibitors

Clinical use and future development of JAKi might need to balance effects on immunological networks, rather than expect that JAKis affect a particular cytokine response and be cued to long-lasting epigenomic modifications rather than by short-term pharmacokinetics.

Biological and clinical significance of the JAK-STAT pathway; lessons from knockout mice

A brief review article is made of the biological and clinical significance of the JAK-STAT pathway, which has turned out to participate in the signalling of numerous other immune and even non-immune mediators.

Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials

An overview of the JAK inhibitors currently under investigation in phase I and II clinical trials for patients with Crohn’s disease and ulcerative colitis and the possible future perspectives for the treatment of IBD patients with this class of drugs are provided.

Immunological Consequences of JAK Inhibition: Friend or Foe?

What is currently known about MPN-associated immune deregulation and JAK inhibitor-mediated immunomodulation is described.

JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?

The aim of this review is to critically review the preclinical and clinical data for the differential selectivity of JAK inhibitors and to summarise the potential clinical implications of the selective JAK inhibitor under development for UC and CD.

Heterodimeric JAK-STAT Activation as a Mechanism of Persistence to JAK2 Inhibitor Therapy

It is shown that JAK2 inhibitor persistence is associated with reactivation of JAK–STAT signalling and with heterodimerization between activatedJAK2 and JAK1 or TYK2, consistent with activation of Jak2 in trans by other JAK kinases.

Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review.

The efficacy of JAK inhibitors in RA is superior to methotrexate in naive patients and equal or superior to adalimumab depending on the drug and dose.